Investors
Mauna Kea Technologies
Stock Information
Mauna Kea Technologies
Stock Information
Stay up to date on all our investor news
0,1662€
Last updated
27/02/2026 - 21:04
-5,78%
€7.6m
Total sales in 2024
+40
Commercial opportunities following CellTolerance launch
+48%
PPU growth in 2024 vs.
2022
excluding exchange rates
Events and Presentations
Financial Results
Governance
Voting Rights Information – January 2026
No results found.
Corporate Presentation January 2026
No results found.
Mauna Kea Technologies announces its 2026 financial calendar highlighted by its participation in several investor forums
No results found.
MKT – Webinar – 15 January 2025
No results found.
Mauna Kea Technologies Reports Strong Q4 2025 Sales Driven by Accelerated Growth in the U.S.
No results found.
News
Mauna Kea Technologies Accelerates International Expansion with New Regulatory Clearances in Switzerland and the United Kingdom
Mauna Kea Technologies Announces CE MDR Certification For Cellvizio® and Its Associated Probes
Mauna Kea Technologies Announces New Commercial Organization to Accelerate Growth Outside the United States
No results found.
Shareholding Structure
A long term vision shared by major strategic shareholders: Johnson & Johnson (NYSE: JNJ) and Telix Pharmaceuticals (ASX : TLX)
Stock Information
STOCK MARKET DATA
Listed on Euronext Growth Paris
Initial listing : July 6, 2011
The number of outstanding shares is : 79,439,997
Industry : healthcare (4000)
Sector : Medical equipment and healthcare services (4530)
IDENTIFICATION CODES
ISIN : FR0010609263
Ticker : ALMKT
ANALYST COVERAGE
ALLINVEST SECURITIES
Thibaut Voglimacci – Stephanopoli
EUROLAND CORPORATE
EUROLAND CORPORATE
Raphaël Génin
STATUTORY AUDITORS
• EY and Others, represented by Mr Franck SEBAG, 1-2 place des Saisons, 92400 Courbevoie- Paris La Défense, France